Sudo Biosciences

About Sudo Biosciences

Sudo Biosciences is a biopharmaceutical company focused on the development of next-generation medicines for neuroinflammatory and autoimmune diseases. The company's primary focus is on targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, a key mediator in the signaling of multiple cytokines involved in inflammation and autoimmune responses.

Sudo Biosciences' lead drug candidate, SUDO-550, is an orally administered, brain-penetrant, allosteric TYK2 inhibitor. This drug is currently in Phase I clinical trials to assess its safety, tolerability, and pharmacokinetics. The company is developing this drug for the treatment of various neuroinflammatory conditions, including multiple sclerosis and Alzheimer's disease. By developing a brain-penetrant TYK2 inhibitor, Sudo Biosciences aims to address the significant unmet medical need for effective treatments for these debilitating diseases.

The company's business model revolves around the research and development of its drug candidates, with the ultimate goal of obtaining regulatory approval and commercializing its products. Sudo Biosciences collaborates with academic institutions and other partners to advance its research and development efforts. The company's target market includes patients with neuroinflammatory and autoimmune diseases, a large and growing market with a significant need for new and improved treatments.